Vanda Pharmaceuticals Inc. (VNDA)
Largest Insider Buys in Sector
VNDA Stock Price History Chart
VNDA Stock Performance
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment …
Insider Activity of Vanda Pharmaceuticals Inc.
Over the last 12 months, insiders at Vanda Pharmaceuticals Inc. have bought $0 and sold $552,533 worth of Vanda Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Vanda Pharmaceuticals Inc. have bought $0 and sold $3.02M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 11,170 shares for transaction amount of $100,156 was made by Flynn James E (10 percent owner) on 2015‑12‑16.
List of Insider Buy and Sell Transactions, Vanda Pharmaceuticals Inc.
| 2024-11-14 | Sale | director | 5,000 0.0086% | $5.17 | $25,863 | 0.00% | ||
| 2024-07-29 | Sale | SVP, CFO & Treasurer | 2,251 0.0038% | $5.92 | $13,327 | -17.67% | ||
| 2024-03-05 | Sale | President and CEO | 24,288 0.0421% | $4.13 | $100,273 | +20.34% | ||
| 2024-03-05 | Sale | SVP, Business Development | 8,684 0.0151% | $4.13 | $35,884 | +20.34% | ||
| 2024-03-05 | Sale | SVP, CFO & Treasurer | 8,902 0.0157% | $4.20 | $37,411 | +20.34% | ||
| 2024-03-05 | Sale | SVP & General Counsel | 8,941 0.0157% | $4.18 | $37,396 | +20.34% | ||
| 2024-03-05 | Sale | SVP, Chief Marketing Officer | 9,229 0.0163% | $4.21 | $38,830 | +20.34% | ||
| 2024-03-04 | Sale | President and CEO | 30,884 0.0534% | $4.24 | $131,066 | +15.89% | ||
| 2024-03-04 | Sale | SVP, Business Development | 8,727 0.0153% | $4.30 | $37,495 | +15.89% | ||
| 2024-03-04 | Sale | SVP, CFO & Treasurer | 5,798 0.0106% | $4.48 | $25,982 | +15.89% | ||
| 2024-03-04 | Sale | SVP & General Counsel | 8,147 0.0146% | $4.41 | $35,917 | +15.89% | ||
| 2024-03-04 | Sale | SVP, Chief Marketing Officer | 7,498 0.0135% | $4.41 | $33,091 | +15.89% | ||
| 2023-08-21 | Sale | SVP, Chief Marketing Officer | 3,724 0.0064% | $5.84 | $21,748 | -26.09% | ||
| 2023-08-10 | Sale | director | 6,500 0.0114% | $6.05 | $39,349 | -27.08% | ||
| 2023-07-28 | Sale | SVP, CFO & Treasurer | 2,212 0.0038% | $6.30 | $13,945 | -25.93% | ||
| 2023-06-15 | Sale | SVP, CFO & Treasurer | 16,000 0.0279% | $6.29 | $100,710 | -29.57% | ||
| 2023-06-13 | Sale | SVP & General Counsel | 14,600 0.0257% | $6.56 | $95,754 | -31.65% | ||
| 2023-03-03 | Sale | President and CEO | 22,538 0.0388% | $6.25 | $140,876 | -19.78% | ||
| 2023-03-03 | Sale | SVP, Business Development | 8,268 0.0143% | $6.26 | $51,791 | -19.78% | ||
| 2023-03-03 | Sale | SVP, CFO & Treasurer | 5,968 0.0103% | $6.28 | $37,499 | -19.78% |
Insider Historical Profitability
| Polymeropoulos Mihael Hristos | President and CEO | 1871730 3.2101% | $4.67 | 5 | 52 | <0.0001% |
| TANG KEVIN C | 10 percent owner | 2715852 4.6578% | $4.67 | 6 | 8 | +419.54% |
| Flynn James E | 10 percent owner | 693171 1.1888% | $4.67 | 5 | 5 | +15.47% |
| Kelly James Patrick | EVP & Chief Financial Officer | 186869 0.3205% | $4.67 | 1 | 14 | <0.0001% |
| Clark William D | Sr. VP, Chief Business Officer | 168279 0.2886% | $4.67 | 1 | 10 | <0.0001% |
Institutional Investor Ownership
| BlackRock | $33.45M | 13.99 | 8.14M | -2.47% | -$848,657.44 | <0.01 | |
| Renaissance Technologies | $17.57M | 7.35 | 4.28M | +16.15% | +$2.44M | 0.03 | |
| The Vanguard Group | $13.96M | 5.84 | 3.4M | -1.75% | -$248,671.42 | <0.0001 | |
| Acadian Asset Management | $9.74M | 4.07 | 2.37M | +4.74% | +$440,510.40 | 0.03 | |
| D. E. Shaw & Co. | $7.41M | 3.1 | 1.8M | -14.64% | -$1.27M | 0.01 |